Last updated: February 27, 2026
What is Relenza (Zanamivir)?
Relenza (zanamivir) is an inhaled antiviral medication approved for the treatment and prevention of influenza A and B infections. Manufactured by GlaxoSmithKline, it is available as a dry powder for inhalation. Relenza holds a significant position among neuraminidase inhibitors, competing primarily with Tamiflu (oseltamivir).
Market Overview
Current Market Size
The global influenza antiviral drugs market was valued at approximately $2.8 billion in 2022. Relenza accounted for an estimated 10-15% of this market, with sales around $300 million to $420 million annually.
Pricing Strategy
Relenza's list price per treatment course in the United States is approximately $120. This is consistent across developed markets but varies globally due to healthcare policies and reimbursement frameworks.
Competitive Landscape
- Tamiflu (oseltamivir): Market leader with about 70-80% market share due to wider approval and ease of oral administration.
- Baloxavir marboxil: New entry with rapid onset, growing rapidly, especially in outpatient settings.
- Others: Peramivir, inhaled Zanamivir (Relenza), and supportive therapies.
Market Drivers and Barriers
Drivers
- Seasonal influenza outbreaks increase demand annually.
- Rising public health awareness about influenza complications.
- Growing use of prophylactic antiviral treatment during pandemics.
Barriers
- Limitations of inhalation delivery due to respiratory conditions.
- Competition from newer drugs with faster onset or simpler administration.
- Patent expiration liabilities and generic entries expected by 2030.
Price Projections
Short-term (Next 2 Years)
- Price stabilization at current levels, barring policy or regulatory changes.
- Potential discounts in emerging markets due to reimbursement negotiations.
Mid-term (3–5 Years)
- Slight decline in list prices due to increased generic competition.
- Expected 10-15% reduction in market price per course as generics enter the market.
Long-term (Beyond 5 Years)
- Possible decline of 20-30% in unit price if biosimilars or alternative delivery methods emerge.
- Price pressure from increased use of oral or injectable alternatives.
Revenue Projections
| Year |
Estimated Market Share |
Average Price per Course |
Projected Revenue |
| 2023 |
12% |
$120 |
$36 million |
| 2025 |
10% |
$108 |
$27 million |
| 2030 |
7% |
$90 |
$15 million |
(Note: These are approximate figures based on market trends and current pricing.)
Regulatory and Patent Dynamics
- The last patent for Relenza is set to expire in 2028 in major markets (US, EU).
- Generic versions expected post-2028 could reduce prices by 30-50%.
- Regulatory approvals for new formulations or delivery methods could influence competitive positioning.
Strategic Outlook
GlaxoSmithKline appears to focus on newer formulations and expanded indications to sustain revenue. Several companies are exploring inhalable combinations and inhaled biologics, which could encroach upon Relenza’s market share post-patent expiry.
Key Takeaways
- Relenza remains a niche but relevant influenza treatment with stable pricing in the short term.
- Market share is declining due to oral alternatives and increased competition.
- Price declines are anticipated upon patent expiration and entry of generics.
- Long-term profitability will depend on portfolio diversification and potential new indications.
FAQs
1. When does Relenza’s patent expire?
Patents for Relenza are set to expire around 2028 in major markets, opening the market for generics.
2. How does Relenza compare to Tamiflu in efficacy?
Both drugs have similar efficacy in treating influenza, but Tamiflu's oral route gives it broader usage, impacting Relenza’s market share.
3. Are there upcoming formulations for Relenza?
Currently, no new formulations are in advanced stages; focus remains on existing inhaled powder.
4. What is the potential impact of biosimilars?
Biosimilars are less relevant for small-molecule drugs like Relenza; generic small-molecule versions are more likely to impact pricing.
5. What markets are emerging for influenza antivirals?
Emerging markets in Asia and Latin America show increased adoption driven by influenza seasons and pandemic preparedness.
References
[1] Grand View Research. (2023). Influenza Antiviral Drugs Market. https://www.grandviewresearch.com/industry-analysis/influenza-antiviral-drugs-market
[2] GlaxoSmithKline. (2022). Relenza (zanamivir)—Product information.
[3] IQVIA. (2022). Global Pharmaceutical Market Data.
[4] U.S. Food and Drug Administration. (2023). Patent and exclusivity data for influenza antivirals.
